Linneo Health expands medicinal cannabis offering to include industrial cannabis DERIVATIVES, following the extraction of EU-GMP certification to Alkalibriit is industrial easey
Linneo Health will expand its offering of medicinal cannabis products to include API and cannabis extracts, under the terms of a CDMO agreement with Alcaliber
Alkalibri CLUE GMP certifiedion for cannabis extracts from the Spanish Agency of Medicines and Medical Products (AEMPS)
Madrid, Spain, July 28 2022: Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and well-being, and Alcaliber, a leading independent supplier of active pharmaceutical ingredients (APIs) to the global pharmaceutical industry, today announce a cannabis extended medicinal. offer from Linneo Health to include industrial derivatives. This follows the issuance of the Good Manufacturing Practice (EU-GMP) certificate for the industrial processing of cannabis derivatives for Alcaliber by the Spanish Agency for Medicines and Medical Products (Agencia Española de Medicamentos y Productos Sanitarios – AEMPS).
EU-GMP certification is recognized by all medicine regulatory agencies within the EU, as well as by a number of leading agencies worldwide.
Under the terms of an exclusive CDMO agreement with Alcaliber, Linneo Health now adds capabilities to supply APIs and finished medicinal dosage forms, such as tetrahydrocannabinol (THC) and standardized cannabis extracts, in addition to existing certified medicinal cannabis flowers from EU-GMP. Alcaliber’s new GMP certification allows for a significant expansion in Linneo Health’s medicinal product offering and ensures that Linneo’s commitment to providing cannabis products of the highest GMP standards extends to cannabis extracts.
Don Bellamy, Chief Executive Officer of Linneo Health, said: “our The ability to supply industrial derivatives at the highest level quality, except for our existing expertise in cultivation and FILING e cannabis flowers for our partners, marks a major expansion in our portfolio and further strengthens our position as a global leader in this field. As medicinal cannabis the market evolves globally, beside a changing landscape of regulatory and legal reforms, Linneo Health is poised to maintain its leadership position a wide one PORTFOLIO The offer of AND a complete service to our customers.”
José Antonio de la Puente, Chief Executive Officer of Alcaliber, said: “Addition of whole industrial cannabis derivatives, from Adrinks to standardized extracts, it’s a big milestone for our company. Bringing our experience of more than 90 years in extraction of Active substances from plant plants is a differential asset in complex the pharmaceutical industry of cannabis. our commitment to the highest standards of quality AND innovationcombined with ours fOCUS in continuous improvement, supported our new family of products.”
Linneo Health offers its customers unmatched experience in the research, cultivation and supply of medicinal cannabis, leveraging a deep heritage of leadership and knowledge in the manufacture of strictly regulated pharmaceutical products. In addition to world-leading pharmaceutical-grade cannabis flowers grown at the Company’s facilities in Southern Spain, Linneo Health gains access to Alcaliber’s 12,000-ton annual processing capacity, enabling the production of high-quality APIs and standardized extracts of cannabis.
Alcaliber sets a benchmark in the industry in terms of quality, innovation, integrity and commitment to its customers. Alcaliber’s mission is to produce and develop natural extracts and APIs to the highest standards, thereby helping the pharmaceutical industry improve the quality of life of millions of people worldwide.
– ENDS –
Requests:
Linnaeus Health
Don Bellamy, CEO Tel: +34 91 700 20 90
Alkalibri
Jose Antonio de la Puente, CEO Tel +34 91 575 46 67
Strategic Planning of Communications
Amber Fennell / David Daley Tel: +44 (0) 20 3709 5700
Linneo@consilium-comms.com
About Linneo Health
Linneo Health is a Europe-based global leader in the research, production and supply of EU-GMP certified cannabis medicinal flowers, extracts and medicinal cannabis products to pharmaceutical partners developing innovative cannabis-based therapies for patients in need. The world’s only vertically integrated supplier of medicinal cannabis, no other company has Linneo’s 90-year legacy in the production and movement of controlled substances. Linneo is optimally positioned to address the needs of its customers at every stage of product development, regulation and handling.
Linneo Health is setting the benchmark for standards and customer service in medicinal cannabis. Through continuous investment in one of the most advanced quality control laboratories in Europe, and applying industry-leading cultivation techniques, Linneo is the trusted partner to address the needs of customers today and, with significant expansion capabilities, the demands of tomorrow. With an unrivaled focus on quality and driven by the strong belief that people around the world deserve to be treated with the highest standard of cannabis medicine, Linneo brings the latest innovations in medicinal cannabis to partners to deliver better results. good for patients and to improve life. www.linneohealth.com
About Alcaliber
Alcaliber is a leading independent supplier of active pharmaceutical ingredients (‘API’) and intermediates to the global pharmaceutical industry. Alcaliber has a 90-year history of best-in-class industrial operations in a highly regulated market with strong barriers to entry.
Alcaliber is a fully integrated leader in its sector with a state-of-the-art manufacturing facility and a reputation for exceptional quality products resulting in strong and sustainable growth.
www.alcaliber.com
